All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @jasminegoode_ on TikTok · 11s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @jasminegoode_'s video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Where

@jasminegoode_'s GLP-1 success story, fact-checked

Jasmine Goode

TikTok creator

84.8K viewsWatch on TikTok

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide slow gastric emptying and reduce appetite through incretin hormone pathways. The STEP 1 trial showed 14.9% average body weight reduction with 2.4mg semaglutide over 68 weeks. Most patients experience gastrointestinal side effects initially, but many report improved quality of life scores as treatment progresses.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @jasminegoode_'s GLP-1 success story, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

@jasminegoode_'s GLP-1 success story, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@jasminegoode_'s GLP-1 success story, fact-checked" from Jasmine Goode. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide slow gastric emptying and reduce appetite through incretin hormone pathways.

The reason this review is not generic is the source wording and the canonical claim label "glp1 never felt better joinfridays weddingcountdown." In this clip, the useful excerpt is: "Where" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

14.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide slow gastric emptying and reduce appetite through incretin hormone pathways.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide slow gastric emptying and reduce appetite through incretin hormone pathways. The STEP 1 trial showed 14.9% average body weight reduction with 2.4mg semaglutide over 68 weeks. Most patients experience gastrointestinal side effects initially, but many report improved quality of life scores as treatment progresses.
  • The STEP 1 trial found 84% of semaglutide users reported improved quality of life scores
  • 14.9% average weight loss occurred over 68 weeks in the STEP 1 trial, not quickly

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • The STEP 1 trial found 84% of semaglutide users reported improved quality of life scores
  • 14.9% average weight loss occurred over 68 weeks in the STEP 1 trial, not quickly
  • 74% of patients experience gastrointestinal side effects like nausea initially
  • Wegovy costs approximately $1,349 per month without insurance coverage
  • 7% of trial participants discontinued semaglutide due to side effects
  • Individual results vary significantly from clinical trial averages
  • The SELECT trial showed 20% reduction in major cardiovascular events with semaglutide

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this video actually claim?

Jasmine Goode posted a brief TikTok saying she's "never felt better" while using hashtags related to GLP-1 medications and a wedding countdown. She doesn't make specific medical claims in her 8-second video.

The post appears to be a personal testimonial about her experience with GLP-1 receptor agonists, likely semaglutide or tirzepatide. Her caption suggests she's preparing for a wedding and feeling good about her progress.

Without explicit claims about weight loss amounts or side effects, there's limited factual content to verify. This is essentially a brief personal update rather than health information.

Do people actually feel better on GLP-1 medications?

Many patients do report feeling better on GLP-1 receptor agonists, and clinical trials back this up. The STEP 1 trial (Wilding et al., NEJM, 2021) found that 84% of participants on 2.4mg semaglutide reported improved quality of life scores.

The SELECT trial (Lincoff et al., NEJM, 2023) showed that semaglutide users had 20% fewer major cardiovascular events compared to placebo. Participants often report increased energy and improved mood as they lose weight.

However, about 74% of people experience gastrointestinal side effects like nausea during the first few months. The STEP 1 trial found that 7% discontinued treatment due to side effects, mostly stomach issues.

What's missing from this type of content?

Jasmine's post doesn't mention the less glamorous parts of GLP-1 treatment. The SUSTAIN 1 trial (Sorli et al., Diabetes Care, 2017) found that 39.3% of semaglutide users experienced nausea during the first 12 weeks.

She also doesn't discuss the significant cost. Wegovy runs about $1,349 per month without insurance, and many insurance plans don't cover it for weight loss. That's over $16,000 annually for most people.

Timeline matters too. The medication works slowly, with peak weight loss typically occurring around 68 weeks in clinical trials. Quick before-and-after content can set unrealistic expectations about how fast results happen.

Should you trust social media testimonials?

Individual success stories like Jasmine's can't tell you much about what to expect. Clinical trials exist because personal experiences vary wildly from the average response.

The STEP 1 trial showed 14.9% average weight loss, but individual results ranged from minimal loss to over 20%. Some people feel amazing on these medications while others struggle with persistent side effects for months.

What's more useful than any single testimonial is looking at large-scale data from randomized controlled trials. Those give you realistic expectations about both benefits and potential downsides you might face.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Jasmine Goode · TikTok creator

84.8K views on this video

Never felt better 💛 #joinfridays #weddingcountdown

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about the step 1 trial found 84% of semaglutide users reported?

The STEP 1 trial found 84% of semaglutide users reported improved quality of life scores

What does the video say about 14.9% average weight loss occurred over 68 weeks in the?

14.9% average weight loss occurred over 68 weeks in the STEP 1 trial, not quickly

What does the video say about 74% of patients experience gastrointestinal side effects like nausea initially?

74% of patients experience gastrointestinal side effects like nausea initially

What does the video say about wegovy costs approximately $1,349 per month without insurance coverage?

Wegovy costs approximately $1,349 per month without insurance coverage

What does the video say about 7% of trial participants discontinued semaglutide due to side effects?

7% of trial participants discontinued semaglutide due to side effects

What does the video say about individual results vary significantly from clinical trial averages?

Individual results vary significantly from clinical trial averages

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Jasmine Goode, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.